NCT02817464View on ClinicalTrials.gov

Study to Evaluate Suppression of Ovulation and Pharmacokinetics of Medroxyprogesterone Acetate Following Administration of TV-46046 in Women With Ovulatory Cycle

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 26, 2016

Primary Completion Date

December 3, 2018

Study Completion Date

December 3, 2018

Conditions

PregnancyContraception

Interventions

DRUG

TV-46046 - 400 mg/mL

A single subcutaneous injection in the abdomen of undiluted TV-46046 - 400 mg/mL

DRUG

TV-46046 - 200 mg/mL

A single subcutaneous injection in the abdomen of saline-diluted TV-46046 - 200 mg/mL

Trial Locations (2)

19104

Teva Investigational Site 001, Philadelphia

23507

Teva Investigational Site 002, Norfolk

All Listed Sponsors

collaborator

FHI 360

OTHER

lead

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

NCT02817464 - Study to Evaluate Suppression of Ovulation and Pharmacokinetics of Medroxyprogesterone Acetate Following Administration of TV-46046 in Women With Ovulatory Cycle | Biotech Hunter | Biotech Hunter